Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions

References

• Barrett A, Roques T, Small M, et al. How much will herceptin really cost? BMJ. 2006Nov25;333(7578):1118–1120. PMID: 17124225; PMCID: PMC1661755.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Misery L, Naeyaert S, et al.Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019Mar28; 10(279):10.3389/fphar.2019.00279 PMID: 30983996; PMCID: PMC6447826
   PubMedGoogle Scholar
• Putrik P, Ramiro S, Kvien TK, et al. Working group equity in access to treatment of rheumatoid arthritis in Europe’. inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014Jan;731:198–206. Epub 2013 Mar 6. PMID: 23467636
   PubMed Web of Science ®Google Scholar
• Kostić M, Djakovic L, Šujić R, et al. Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017Feb;151:85–93. PMID: 27587010; PMCID: PMC5253143
   PubMed Web of Science ®Google Scholar
• Liao JM, Fischer MA. Restrictions of Hepatitis c treatment for substance-using Medicaid patients: cost versus ethics. Am J Public Health. 2017;107(6):893–899.
   PubMed Web of Science ®Google Scholar
• Chou JW, Silverstein AR, Goldman DP. Short-term budget affordability of Hepatitis C treatments for state Medicaid programs. BMC Health Serv Res. 2019Feb28;19(1):140. PMID: 30819153; PMCID: PMC6394005.
   PubMedGoogle Scholar
• Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791–794.
   PubMed Web of Science ®Google Scholar
• Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017 Oct 4. 359(j4543). PMID: 28978508; PMCID: PMC5695518. 10.1136/bmj.j4543
   Google Scholar
• Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–540. Epub ahead of print. PMID: 33535841.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014 Jan-Feb;17(1):5–14. Epub 2013 Dec 13. PMID: 24438712.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoecon Outcomes Res. 2005Feb5;5(1):65–79. PMID: 19807561.
   PubMedGoogle Scholar
• Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Pharmacoeconomics. 2008;26(6):477–495. PMID: 18489199.
   PubMed Web of Science ®Google Scholar
• Rodwin MA. How the United Kingdom controls pharmaceutical prices and spending: learning from its experience. Int J Health Serv. 2021Apr;51(2):229–237. Epub 2021 Mar 25. PMID: 33764174.
   PubMed Web of Science ®Google Scholar
• Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011Dec;12(6):499–502. PMID: 21874376.
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Mittendorf T, Persson U. Practical issues in handling data input and uncertainty in a budget impact analysis. Eur J Health Econ. 2011 Jun 3;12(3):231–241. Epub 2010 April 3. PMID: 20364289; PMCID: PMC3078307.
   PubMed Web of Science ®Google Scholar
• Flume M, Bardou M, Capri S, et al. Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries. J Mark Access Health Policy. 2018Jun8;6(1):1478539. PMID: 29915664; PMCID: PMC5998770.
   PubMedGoogle Scholar
• Wettermark B, Persson ME, Wilking N, et al.Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010May17; 10(128):10.1186/1472-6963-10-128 PMID: 20478043; PMCID: PMC2893175
   PubMedGoogle Scholar
• MacBride-Stewart SMS, Kurdi A, Sneddon J, et al. Initiatives and reforms across Scotland in recent years to improve prescribing; findings and global implications of drug prescriptions. Int J Clin Exp Med. 2021;14(12):2563–2586.
   Web of Science ®Google Scholar
• Linnér L, Eriksson I, Persson M, et al. Forecasting drug utilization and expenditure: ten years of experience in Stockholm. BMC Health Serv Res. 2020;20(1):410.
   PubMed Web of Science ®Google Scholar
• Lee M, Ly H, Möller CC, et al. Innovation in regulatory science is meeting evolution of clinical evidence generation. Clin Pharmacol Ther. 2019Apr;105(4):886–898. PMID: 30636288; PMCID: PMC6593618.
   PubMed Web of Science ®Google Scholar
• IQVIA. The global use of medicine in 2019 and outlook to 2023 - forecasts and areas to watch. 2019. [ cited 2019 Jan 15]. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf
   Google Scholar
• Pontes C, Zara C, Torrent-Farnell J, et al. Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the Case of Olaratumab. Appl Health Econ Health Policy. 2020Feb;181:5–16. PMID: 31696433
   PubMed Web of Science ®Google Scholar
• Haycox A. Why Cancer? Pharmacoeconomics. 2016Jul;34(7):625–627. PMID: 27194312; PMCID: PMC4901109.
   PubMed Web of Science ®Google Scholar
• Eriksson I, Wettermark B, Bergfeldt K. Real-world use and outcomes of Olaparib: a population-based cohort study. Target Oncol. 2018Dec;13(6):725–733. PMID: 30446872; PMCID: PMC6297279.
   PubMed Web of Science ®Google Scholar
• Godman B, Malmstrom RE, Diogene E, et al.Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014Jun10; 5(109):10.3389/fphar.2014.00109 PMID: 24959145; PMCID: PMC4050532
   Google Scholar
• Eriksson I, Wettermark B, Persson M, et al.The early awareness and alert system in Sweden: history and current status. Front Pharmacol. 2017Oct5; 8(674):10.3389/fphar.2017.00674 PMID: 29056910; PMCID: PMC5635816
   Google Scholar
• Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic Hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018Jul;747:971–978. Epub 2018 Apr 9. PMID: 29632961; PMCID: PMC5999144
   PubMed Web of Science ®Google Scholar
• Lai AG, Pasea L, Banerjee A, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020Nov17;10(11):e043828. PMID: 33203640; PMCID: PMC7674020.
   PubMed Web of Science ®Google Scholar
• van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014Feb;121:33–40. PMID: 24158922
   PubMedGoogle Scholar
• Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics. 2009;27(10):807–827. PMID: 19803537.
   PubMed Web of Science ®Google Scholar
• Faleiros DR, Álvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):257–266. Epub 2016 Mar 17. PMID: 26923561.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Earnshaw S, Methodological A. Review of US budget-impact models for new drugs. Pharmacoeconomics. 2016Nov;34(11):1111–1131. PMID: 27334107.
   PubMed Web of Science ®Google Scholar
• Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017Oct;3510:1047–1062. PMID: 28660473; PMCID: PMC5606961
   PubMed Web of Science ®Google Scholar
• Brazil, Ministry of Health. Ministry of Health - Secretariat of Health Surveillance - Department of STD, AIDS and Viral Hepatitis. Epidemiological bulletin “Viral Hepatitis.” Ministério da Saúde.1, 2011. cited 2020 Feb 11. Available. http://www.aids.gov.br/pt-br/node/92.
   Google Scholar
• Brazil Ministry of Health. Secretariat of Science, Technology and Strategic Inputs. Recommendation report of the national commission for the incorporation of technologies in SUS - CONITEC - 01 protease inhibitors (Boceprevir and Telaprevir) for the treatment of chronic Hepatitis C. Ministério da Saúde. July 2012. cited 2020 May 15]. Available at: http://conitec.gov.br/images/Relatorios/2012/Boceprevir_Telaprevir_final.pdf
   Google Scholar
• Taieb V, Pacou M, Ho S, et al. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus. J Med Econ. 2015;18(10):787–796. Epub 2015 May 26. PMID: 25934147.
   PubMed Web of Science ®Google Scholar
• de Bruijn W, Ibanez C, Frisk P, et al. Introduction and utilization of high priced HCV medicines across Europe; implications for the future. Front Pharmacol. 2016 Jul 22;7:197. PMID: 27516740; PMCID: PMC4964878.
   PubMed Web of Science ®Google Scholar
• Liang TJ, Ghany MG. Current and future therapies for Hepatitis C virus infection. N Engl J Med. 2013 May 16;368(20):1907–1917. PMID: 23675659; PMCID: PMC3893124.
   PubMed Web of Science ®Google Scholar
• Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14(Suppl6):S5. Epub 2014 Sep 19. PMID: 25253373; PMCID: PMC4178584.
   PubMedGoogle Scholar
• Brennan T, Shrank W. New expensive treatments for Hepatitis C infection. JAMA. 2014 Aug 13;312(6):593–594. PMID: 25038617.
   PubMed Web of Science ®Google Scholar
• Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing Hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014Apr;587:928–936. Epub 2014 Jan 6. PMID: 24399087; PMCID: PMC3952605
   PubMed Web of Science ®Google Scholar
• Andrieux-Meyer I, Cohn J, de Araújo ES, et al. Disparity in market prices for Hepatitis C virus direct-acting drugs. Lancet Glob Health. 2015Nov;311:e676–7. PMID: 26475012
   PubMed Web of Science ®Google Scholar
• Brazil. Constitution of the federative republic of Brazil. September 5, 1988. Diário Oficial [da] União. Brasília DF: Senado Federal. 1988. 292 cited 2019 Dec 11]. 2019 Dec 11 Available: http://www.planalto.gov.br/ccivil_03/constituicao/constituicaocompilado.htm
   Google Scholar
• Marten R, McIntyre D, Travassos C, et al. An assessment of progress towards universal health coverage in Brazil, Russia, India, China, and South Africa (BRICS). Lancet. 2014 Dec 13;384(9960):2164–2171. Epub 2014 Apr 30. PMID: 24793339; PMCID: PMC7134989.
   PubMed Web of Science ®Google Scholar
• Paim J, Travassos C, Almeida C, et al. The Brazilian health system: history, advances, and challenges. Lancet. 2011May21;377(9779):1778–1797. Epub 2011 May 9. PMID: 21561655.
   PubMed Web of Science ®Google Scholar
• Lemos LLP, Guerra Júnior AA, Santos M, et al. the assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil. Pharmacoeconomics. 2018Feb;362:161–173. PMID: 29139001; PMCID: PMC5805817
   PubMed Web of Science ®Google Scholar
• Guimarães R. Technological incorporation in the unified health system (SUS): the problem and ensuing challenges. Cien Saude Colet. 2014Dec;19(12):4899–4908. PMID: 25388198.
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. Ordinance no. 009, of September 13, 2012. Approves the internal regulations of the National Commission for Incorporating Technologies in the Unified Health System (CONITEC). Diário Oficial [da] União, Poder Executivo, Brasília, DF, 14 set. 2012. 2020 May 19]. cited: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2012/prt2009_13_09_2012.html
   Google Scholar
• Yuba TY, Novaes HMD, de Soárez P. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations. Health Res Policy Syst. 2018 May 11;16(1):40. PMID: 29751764; PMCID: PMC5948855.
   PubMedGoogle Scholar
• Brazil. Ministry of Jealth. Secretariat of Science, Technology and Strategic Inputs. Department of Science and Technology. Methodological guidelines - budget impact: analysis guidelines for the Brazilian health system. Ministério da Saúde. 2012. 76 (Series A: Standards and technical manuals). 2020 May 21]. cited: http://bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_analise_impacto.pdf
   Google Scholar
• Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19(6):609–621. PMID: 11456210.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health. 2007Sep-Oct;10(5):336–347. PMID: 17888098
   PubMed Web of Science ®Google Scholar
• Vargas-Pelaez CM, Rover MRM, Soares L, et al. Judicialization of access to medicines in four Latin American countries: a comparative qualitative analysis. Int J Equity Health. 2019 Jun 3;18(1):68. PMID: 31154999; PMCID: PMC6545681.
   PubMedGoogle Scholar
• de Souza Al C, de Assis Acurcio F, Guerra Junior AA, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014Feb;121:19–32. PMID: 24385261
   PubMedGoogle Scholar
• Marra LP, Araujo VE, Oliveira GC, et al. The clinical effectiveness of insulin glargine in patients with Type I diabetes in Brazil: findings and implications. J Comp Eff Res. 2017Sep;66:519–527. Epub 2017 Sep 29. PMID: 28960085
   PubMed Web of Science ®Google Scholar
• de Oliveira G, Guerra Júnior AA, Godman B, et al. Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev Pharmacoecon Outcomes Res. 2017Apr;172:109–119. Epub 2017 Feb 22. PMID: 28403729
   PubMed Web of Science ®Google Scholar
• Brazil. Ministry of Health. Health Surveillance Secretariat. Department of STD, AIDS and Viral Hepatitis. Clinical protocol and therapeutic guidelines for viral Hepatitis C and co-infections/Ministry of Health. Secretariat of Health Surveillance, Department of STD, AIDS and Viral Hepatitis. Brasilia: Ministério da Saúde; 2010. [cited 2019 Dec 11]. Available 2019 Dec 11. 144 for.150: il. - (Serie A. Standards and Technical Manuals).http://bvsms.saude.gov.br/bvs/publicacoes/protocolos_diretrizes_hepatite_viral_c_coinfeccoes.pdf
   Google Scholar
• Brazil. executive secretariat of the medicines market regulation chamber - CMED. Communiqué 6 of September 52013.Brasília,Diário Oficial [da] União September 10, 2013, Section 3, p. 3. Accessed 2 May 2019: http://portal.anvisa.gov.br/documents/374947/2932238/Comunicado+n%C2%BA+6%2C+de+5+de+setembro+de+2013.pdf/92ecd43a-aa94-4dfa-839e-c144dc7c17af
   Google Scholar
• Cherchiglia ML, Guerra Júnior AA, Andrade EIG, et al. The construction of the national database on renal replacement therapy (RRT) centered on the individual: application of the deterministic-probabilistic linkage method. Rev Bras Estud Popul. 2007;24:163–167.
   Google Scholar
• Acurcio FA, Brandão CMR, Guerra Júnior AA, et al. Perfil demográfico y epidemiológico de los usuarios de medicamentos de costo elevado en el Sistema Único de Salud. Rev. bras estud Popul. 2009; V26: 263.42.
   Google Scholar
• Guerra Junior AA, Acúrcio FA, Andrade EI, et al. Ciclosporina versus tacrolimus no transplante renal no Brasil: uma comparação de custos [Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison]. Cad Saude Publica. 2010 Jan;26(1):163–174. Portuguese. PMID: 20209220.
   PubMed Web of Science ®Google Scholar
• Gomes RM, Guerra Júnior AA, Lemos LL, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. Expert Rev Clin Pharmacol. 2016Jul;97:991–999. Epub 2016 Jun 16. PMID: 27181131
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Costa JO, de Lemos LLP, et al. Costs in the treatment of Schizophrenia in adults receiving atypical antipsychotics: An 11-year cohort in Brazil. Appl Health Econ Health Policy. 2018Oct;165:697–709. PMID: 30051254; PMCID: PMC6132453
   PubMed Web of Science ®Google Scholar
• Barbosa WB, Gomes RM, Godman B, et al. Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications. Expert Rev Clin Pharmacol. 2021Feb;142:269–279. Epub 2020 Dec 31. PMID: 33331189
   PubMed Web of Science ®Google Scholar
• Acurcio FA, Guerra Junior AA, da Silva MRR, et al. Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Epub 2020 Feb 11. PMID: 31990224, Curr Med Res Opin. 2020 Apr;36(4):677–686.
   PubMed Web of Science ®Google Scholar
• Queiroz OV, Guerra Jr AA, Machado CJ, et al. Record linkage of large data sources: parameter estimation and results validation, applied to the linkage of high complexity procedures authorizations with the hospital information system. Cien Saude Colet. 18(2): 298–308. [2019 Dec 12]. cited. http://www.cadernos.iesc.ufrj.br/cadernos/images/csc/2010_2/artigos/CSCv18n2_298-308.pdf.
   Google Scholar
• Garcia MM, Barbosa WB, Barbosa MM, et al. Survey of values of acquisition of medicines of the specialized component of pharmaceutical assistance in Brazil -. Report number: 01/2018. 2018. 2019 Dec 2]. Available 10.13140/RG.2.2.11678.02885.
   Google Scholar
• The World Bank. PPP conversion factor. 2019 May 2]. Available: https://data.worldbank.org/indicator/PA.NUS.PPP
   Google Scholar
• GC C, Cgso C, MA O. Public procurement of Hepatitis C medicines in Brazil from 2005 to 2015. Cien Saude Colet. 2017 Aug;22(8):2527–2538.
   PubMed Web of Science ®Google Scholar
• Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758. Epub 2015 Sep 14. PMID: 26368060.
   PubMed Web of Science ®Google Scholar
• Godman B, Joppi R, Bennie M, et al. Managed introduction of new drugs Chapter . Vol. 20: 210–221. Elseviers M, Wettermark B, et al. editors, Drug utilization research: methods and applications. John Wiley & Sons: Chichester. 2016. 978(1):118.
   Google Scholar
• Ho H, Janjua NZ, McGrail KM, et al. Hepatitis testers cohort team, Law MR. The impact of public coverage of newer Hepatitis C medications on utilization, adherence, and costs in British Columbia. PLoS One. 2021 Mar 1;16(3):e0247843. PMID: 33647068; PMCID: PMC7920374.
   PubMed Web of Science ®Google Scholar
• Ferreira-da-silva AL, Ribeiro RA, Santos VC, et al. Diretriz para análises de impacto orçamentário de tecnologias em saúde no Brasil [Guidelines for budget impact analysis of health technologies in Brazil]. Cad Saude Publica. 2012 Jul;28(7):1223–1238. Portuguese. PMID: 22729254.
   PubMed Web of Science ®Google Scholar
• Foroutan N, Tarride JE, Xie F, et al. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. Clinicoecon Outcomes Res. 2018 Nov 26;10:821–854. PMID: 30538513; PMCID: PMC6263295.
   PubMed Web of Science ®Google Scholar
• Urrutia J, Porteny T, Daniels N. What does it mean to put new Hepatitis C drugs on a list of essential medicines? BMJ. 2016 Apr 22;353:i2035. PMID: 27106956.
   PubMedGoogle Scholar
• Iyengar S, Tay-Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016 May 31;13(5):e1002032. PMID: 27243629; PMCID: PMC4886962.
   PubMed Web of Science ®Google Scholar
• Geenen JW, Boersma C, Klungel OH, et al. Accuracy of budget impact estimations and impact on patient access: a Hepatitis C case study. Eur J Health Econ. 2019Aug;20(6):857–867. Epub 2019 Apr 5. PMID: 30953216; PMCID: PMC6652171
   PubMed Web of Science ®Google Scholar
• Bilinski A, Neumann P, Cohen J, et al. When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLoS Med. 2017 Oct 2;14(10):e1002397. PMID: 28968399; PMCID: PMC5624570.
   PubMed Web of Science ®Google Scholar
• Sooksriwong C, Chanjaruporn F. Budget impact analysis: a difference between theory and practice. Pharmaceutical Sciences Asia. 2011; 38 (3–4), 34–40. [cited 2019 Dec 5]. https://www.pharmacy.mahidol.ac.th/journal/_files/2011-38-2_34-40.pdf.
   Google Scholar
• Tavares NUL, Bertoldi AD, Mengue SS, et al. Factors associated with low adherence to medicine treatment for chronic diseases in Brazil. Rev Saude Publica. 2016Dec;50(suppl 2):10s. PMID: 27982378; PMCID: PMC5157921
   PubMed Web of Science ®Google Scholar
• Malmström RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013 May 14;4:39. PMID: 23717279; PMCID: PMC3653065.
   PubMed Web of Science ®Google Scholar
• Schneiders RE, Ronsoni RM, Sarti FM, et al. Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System. Cad Saude Publica. 2016Oct10;32(9):e00067516. Erratum in: Cad Saude Publica. 2016 Dec 01;32(11):eER011116.PMID: 27759793.
   PubMed Web of Science ®Google Scholar
• Rcrm N, Álvares J, Guerra JAA, et al.Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev Saude Publica. 2017Nov13; 51(suppl 2):10.11606/S1518-8787.2017051007062 PMID: 29160448; PMCID: PMC567635284.
   Google Scholar
• Iwanczuk T, Zawodnik S, Tatara T, et al. Reliability of manufacturers’ Budget impact estimates for chronic HCV Gt1 Drugs in Poland. Value Health. 2015;18(7):A595.
   Web of Science ®Google Scholar
• Brasil. Ministry of Health (MS). Conitec Report No. 164: Sofosbuvir, daclatasvir and simeprevir for the treatment of chronic viral Hepatitis C. Ministry of Health. 2015. cited 2019 Dec 2]. 2019 Dec 2 Available: http://conitec.gov.br/images/Relatorios/2015/Antivirais_HepatiteC_final.pdf
   Google Scholar
• Caetano R, Silva RMD, Pedro ÉM, et al. Incorporation of new medicines by the National Commission for Incorporation Of Technologies, 2012 to June 2016. Cien Saude Colet. 2017Aug;228:2513–2525. PMID: 28793068
   PubMed Web of Science ®Google Scholar
• Zampirolli DC, Godman B, Gargano LP, et al. Integrative review of managed entry agreements: Chances and limitations. Pharmacoeconomics. 2020Nov;3811:1165–1185. PMID: 32734573
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Matter-Walstra K, Sugahara, T, et al. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. Cost Eff Resour Alloc. 2020;18(1):15.
   PubMed Web of Science ®Google Scholar
• Jakovljevic M, Ogura S. Health economics at the crossroads of centuries – from the past to the future. Front Public Health. 2016;4:115.
   PubMed Web of Science ®Google Scholar
• Ogura S, Jakovljevic M. Health financing constrained by population aging - an opportunity to learn from Japanese Experience/Finansiranje Zdravstvene Zaštite U Uslovima Starenja Popualcije - Prilika Da Učimo Na Japanskom Iskustvu. Serb J ExpClin Res. 2014;15(4):175–181.
   Google Scholar
• Jakovljevic M, Wu W, Merrick J, et al. Asian innovation in pharmaceutical and medical device industry – beyond tomorrow. J Med Econ. 2021;24(sup1):42–50.
   PubMedGoogle Scholar
• Jakovljevic M, Sugahara T, Timofeyev Y, et al. Predictors of (in)efficiencies of healthcare expenditure among the leading Asian economies - comparison of OECD and non-OECD nations. Risk Manag Healthc Policy. 2020;13:2261–2280. Published 2020 Oct 21.
   PubMed Web of Science ®Google Scholar
• Micah AE, Su Y, Bachmeier SD, et al. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards sustainable development goal 3. Lancet. 2020;396(10252):693–724.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Zhang C, Swe KT, et al. Disease-specific out-of-pocket healthcare expenditure in urban Bangladesh: A Bayesian analysis. PloS one. 2020;15(1):e0227565–e.
   PubMed Web of Science ®Google Scholar
• Kastor A, Mohanty SK. Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: Do Indian households face distress health financing? PloS one. 2018;13(5):e0196106–e.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994-2014. BMJ open. 2018;8(5):e018020.
   PubMed Web of Science ®Google Scholar
• Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges. Eur J Health Econ. 2018Mar;19(2):173–175. Epub 2017 Oct 14. PMID: 29032482.
   PubMed Web of Science ®Google Scholar